{"id":10065,"date":"2020-03-23T14:52:19","date_gmt":"2020-03-23T14:52:19","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=10065"},"modified":"2020-12-14T17:58:16","modified_gmt":"2020-12-14T22:58:16","slug":"application-to-fda-for-lonafarnib-approval-is-done","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/it\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","title":{"rendered":"La richiesta di approvazione del lonafarnib alla FDA \u00e8 COMPLETATA!"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;3.22&#8243;][et_pb_row _builder_version=&#8221;3.25&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text admin_label=&#8221;FDA&#8221; _builder_version=&#8221;4.3.4&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;]<\/p>\n<p style=\"font-weight: 400;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-10068  alignleft\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA-300x265.jpg\" alt=\"\" width=\"206\" height=\"182\" \/>La richiesta di approvazione del lonafarnib alla FDA \u00e8 COMPLETATA!\u00a0\u00a0\u00a0<\/strong><\/p>\n<p style=\"font-weight: 400;\">In un periodo altrimenti difficile per il nostro mondo, sono felice di condividere un momento positivo: Eiger BioPharmaceuticals ha completato la presentazione di una domanda di nuovo farmaco (NDA), cercando di ottenere l&#039;approvazione, in Europa e negli Stati Uniti, del farmaco lonafarnib come primo trattamento in assoluto per la Progeria.<\/p>\n<p style=\"font-weight: 400;\">Questa presentazione \u00e8 il risultato di dodici anni di dati di ricerca e quattro sperimentazioni cliniche, tutti finanziati dalla PRF e resi possibili dai coraggiosi bambini e dalle loro famiglie, nonch\u00e9 dalla meravigliosa comunit\u00e0 di donatori della PRF.<\/p>\n<p style=\"font-weight: 400;\">Puoi leggere di pi\u00f9 su questa entusiasmante notizia\u00a0<a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/PRF-Lonafarnib-NDA-Completion-Press-Release-final-PDF-3-23-20.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/PRF-Lonafarnib-NDA-Completion-Press-Release-final-PDF-3-23-20.pdf&amp;source=gmail&amp;ust=1585060548571000&amp;usg=AFQjCNE_6Qu8yUr9CDSuYvEVeGJXwXtlYA\">Qui<\/a>.<\/p>\n<p style=\"font-weight: 400;\">La nostra speranza \u00e8 che questo farmaco venga approvato, consentendo a questi bambini e giovani adulti di accedere al lonafarnib, che ha dimostrato di dare loro cuori pi\u00f9 forti e vite pi\u00f9 lunghe, tramite prescrizione medica, anzich\u00e9 tramite una sperimentazione clinica.<\/p>\n<p style=\"font-weight: 400;\">Sebbene il 2020 sia iniziato come un anno difficile per molti, siamo felici di condividere con voi una buona notizia. Tutti noi della Progeria Research Foundation abbiamo lavorato instancabilmente per avere un impatto significativo sulla vita dei bambini e dei giovani adulti affetti da Progeria.<\/p>\n<p style=\"font-weight: 400;\">GRAZIE A TUTTI per aver sostenuto la ricerca che non solo ci ha portato a questo punto cruciale, ma ci consente anche di continuare a lavorare per scoprire nuovi farmaci che alla fine cureranno questi bambini straordinari.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>In un periodo altrimenti difficile per il nostro mondo, siamo lieti di condividere un momento positivo: Eiger BioPharmaceuticals ha completato la presentazione di una domanda di nuovo farmaco (NDA), chiedendo l&#039;approvazione, in Europa e negli Stati Uniti, del farmaco lonafarnib come primo trattamento in assoluto per la Progeria.<\/p>","protected":false},"author":2,"featured_media":10068,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-10065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/it\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/it\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-23T14:52:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-14T22:58:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"529\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"Application to FDA for lonafarnib approval is COMPLETE!\",\"datePublished\":\"2020-03-23T14:52:19+00:00\",\"dateModified\":\"2020-12-14T22:58:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\"},\"wordCount\":294,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\",\"name\":\"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"datePublished\":\"2020-03-23T14:52:19+00:00\",\"dateModified\":\"2020-12-14T22:58:16+00:00\",\"description\":\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"width\":600,\"height\":529},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Application to FDA for lonafarnib approval is COMPLETE!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/it\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation","description":"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/it\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","og_locale":"it_IT","og_type":"article","og_title":"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation","og_description":"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/it\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2020-03-23T14:52:19+00:00","article_modified_time":"2020-12-14T22:58:16+00:00","og_image":[{"width":600,"height":529,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"Application to FDA for lonafarnib approval is COMPLETE!","datePublished":"2020-03-23T14:52:19+00:00","dateModified":"2020-12-14T22:58:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"},"wordCount":294,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","articleSection":["News"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","url":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","name":"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","datePublished":"2020-03-23T14:52:19+00:00","dateModified":"2020-12-14T22:58:16+00:00","description":"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","width":600,"height":529},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"Application to FDA for lonafarnib approval is COMPLETE!"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"Fondazione per la ricerca sulla progeria","description":"Per i bambini \u2665 Per la cura","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"Fondazione per la ricerca sulla progeria","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"Karen Betournay","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/it\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/posts\/10065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/comments?post=10065"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/posts\/10065\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/media\/10068"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/media?parent=10065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/categories?post=10065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/tags?post=10065"}],"curies":[{"name":"parola chiave","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}